ATE233096T1 - Zusammensetzungen und methoden zur steigerung der darmfunktion - Google Patents

Zusammensetzungen und methoden zur steigerung der darmfunktion

Info

Publication number: ATE233096T1
Authority: AT; Austria
Prior art keywords: methods; compositions; glp; intestinal function; increase intestinal
Prior art date: 1996-12-10

Application number

AT97946986T

Other languages

English (en)

Inventor

Daniel J Drucker

Original Assignee

Ontario Inc 1149336

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-12-10

Filing date

1997-12-10

Publication date

2003-03-15

1997-12-10 Application filed by Ontario Inc 1149336 filed Critical Ontario Inc 1149336

2003-03-15 Application granted granted Critical

2003-03-15 Publication of ATE233096T1 publication Critical patent/ATE233096T1/de

Links

230000003871 intestinal function Effects 0.000 title 1
239000000203 mixture Substances 0.000 title 1
102400000326 Glucagon-like peptide 2 Human genes 0.000 abstract 3
101800000221 Glucagon-like peptide 2 Proteins 0.000 abstract 3
TWSALRJGPBVBQU-PKQQPRCHSA-N glucagon-like peptide 2 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=CC=C1 TWSALRJGPBVBQU-PKQQPRCHSA-N 0.000 abstract 3
239000000813 peptide hormone Substances 0.000 abstract 3
210000002429 large intestine Anatomy 0.000 abstract 2
210000000813 small intestine Anatomy 0.000 abstract 2
208000018522 Gastrointestinal disease Diseases 0.000 abstract 1
230000002708 enhancing effect Effects 0.000 abstract 1
235000016709 nutrition Nutrition 0.000 abstract 1
208000030212 nutrition disease Diseases 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
210000002966 serum Anatomy 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Endocrinology (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Diabetes (AREA)
Chemical Kinetics & Catalysis (AREA)
Molecular Biology (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Hematology (AREA)
Obesity (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

AT97946986T 1996-12-10 1997-12-10 Zusammensetzungen und methoden zur steigerung der darmfunktion ATE233096T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US08/763,177 US5952301A (en)	1996-12-10	1996-12-10	Compositions and methods for enhancing intestinal function
PCT/CA1997/000945 WO1998025644A1 (en)	1996-12-10	1997-12-10	Compositions and methods for enhancing intestinal function

Publications (1)

Publication Number	Publication Date
ATE233096T1 true ATE233096T1 (de)	2003-03-15

Family

ID=25067085

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT97946986T ATE233096T1 (de)	1996-12-10	1997-12-10	Zusammensetzungen und methoden zur steigerung der darmfunktion

Country Status (10)

Country	Link
US (1)	US5952301A (de)
EP (1)	EP0944396B1 (de)
AT (1)	ATE233096T1 (de)
AU (1)	AU5220098A (de)
CA (1)	CA2274596C (de)
DE (1)	DE69719360T2 (de)
DK (1)	DK0944396T3 (de)
ES (1)	ES2193406T3 (de)
PT (1)	PT944396E (de)
WO (1)	WO1998025644A1 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20020025933A1 (en) *	1996-08-30	2002-02-28	Knudsen Liselotte Bjerre	GLP-2 derivatives
CA2236519C (en) *	1997-05-02	2011-09-13	1149336 Ontario Inc.	Methods of enhancing functioning of the large intestine
ATE253375T1 (de) *	1997-05-16	2003-11-15	Ontario Inc 1149336	Verwendung von glp-2 agonisten zur verbesserung der wirkung des oberen gastrointestinaltraktes
EP1052994A2 (de) *	1998-02-02	2000-11-22	Trustees Of Tufts College	Verwendung von dipetidylpeptidasehemmer zur regulierung des glukosemetabolismus
AU7421598A (en) *	1998-05-11	1999-11-29	1149336 Ontario Inc.	Methods of enhancing functioning of the large intestine
US6979697B1 (en)	1998-08-21	2005-12-27	Point Therapeutics, Inc.	Regulation of substrate activity
CA2339537A1 (en) *	1998-08-21	2000-03-02	Barbara Wallner	Regulation of substrate activity
GB9906714D0 (en)	1999-03-23	1999-05-19	Ferring Bv	Compositions for improving fertility
GB9906715D0 (en)	1999-03-23	1999-05-19	Ferring Bv	Compositions for promoting growth
US6890904B1 (en)	1999-05-25	2005-05-10	Point Therapeutics, Inc.	Anti-tumor agents
HK1046846A1 (zh) *	1999-05-25	2003-01-30	Point Therapeutics, Inc.	包含boroproline的抗肿瘤复合物
EP1806138A1 (de) *	1999-05-25	2007-07-11	Point Therapeutics, Inc.	Anti-tumor präparate enthaltend boroprolin verbindungen
ATE381343T1 (de) *	1999-11-03	2008-01-15	Novo Nordisk As	Verwendung eines wachstumshormons oder eines wachstumshormon-sekretion fördernden mittels zur appetit-unterdrückung bzw. sättigungsinduktion
WO2001032199A1 (en)	1999-11-05	2001-05-10	Rogoff Joseph A	Secretin and secretin pharmaceuticals for treating lactose intolerance
GB9930882D0 (en) *	1999-12-30	2000-02-23	Nps Allelix Corp	GLP-2 formulations
US20080249016A1 (en) *	2000-09-18	2008-10-09	Sanos Bioscience A/S	Use of GLP-2 in a combination treatment for bone-related disorders
PT1326630E (pt)	2000-09-18	2008-09-02	Sanos Bioscience As	Utilização de péptidos glp-2
US20070135345A1 (en) *	2000-09-18	2007-06-14	Henriksen Dennis B	Use of GLP-2 for the treatment or prevention, of bone-related disorders
US7371721B2 (en) *	2000-09-18	2008-05-13	Sanos Bioscience A/S	Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
DK1360202T3 (da) *	2001-02-16	2008-09-22	Conjuchem Biotechnologies Inc	Langvarigt glucagon-lignende peptid 2 (GLP-2) til behandling af gastrointestinale sygdomme og lidelser
JP4771661B2 (ja) *	2001-11-26	2011-09-14	トラスティーズオブタフツカレッジ	Ｐｏｓｔ−プロリン開裂酵素の擬ペプチド性阻害剤
EP2769715A3 (de) *	2001-11-26	2014-09-17	Trustees Of Tufts College	Verfahren zur Behandlung von Autoimmunkrankheiten und damit zusammenhängende Reagenzien
US20040038864A1 (en) *	2002-06-27	2004-02-26	Per Balschmidt	Use of dimethyl sulfone as isotonicity agent
US7411039B2 (en) *	2002-10-14	2008-08-12	Novo Nordisk A/S	GLP-2 compounds, formulations, and uses thereof
US20050026859A1 (en) *	2002-11-12	2005-02-03	John Hilfinger	Methods and compositions of gene delivery agents for systemic and local therapy
US20080026077A1 (en) *	2002-11-12	2008-01-31	John Hilfinger	Methods and compositions of gene delivery agents for systemic and local therapy
AU2004288831B2 (en) *	2003-11-12	2010-08-26	Phenomix Corporation	Heterocyclic boronic acid compounds
US7767828B2 (en) *	2003-11-12	2010-08-03	Phenomix Corporation	Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7317109B2 (en) *	2003-11-12	2008-01-08	Phenomix Corporation	Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7576121B2 (en) *	2003-11-12	2009-08-18	Phenomix Corporation	Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US20080269311A1 (en) *	2004-07-14	2008-10-30	Edwin Bernard Villhauer	Combination of Dpp-Iv Inhibitors and Compounds Modulating 5-Ht3 and/or 5-Ht4 Receptors
DE602006020123D1 (de)	2005-05-04	2011-03-31	Zealand Pharma As	Glucagon-like-peptide-2- (glp-2-) analoga
US7825139B2 (en) *	2005-05-25	2010-11-02	Forest Laboratories Holdings Limited (BM)	Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
AU2007319066B2 (en)	2006-11-08	2013-09-19	Zealand Pharma A/S	Selective glucagon-like-peptide-2 (GLP-2) analogues
US20110295151A1 (en) *	2010-05-26	2011-12-01	Bakos Gregory J	Enteroendocrine Manipulation for Metabolic Effect
EA028929B1 (ru)	2012-05-03	2018-01-31	Зилэнд Фарма А/С	Аналоги глюкагоноподобного пептида-2 (glp-2)
EP4219534A3 (de)	2013-07-08	2023-09-27	The University of Utah Research Foundation	Verfahren zur behandlung von und vorbeugung gegen entzündliche erkrankungen
US20180200301A1 (en) *	2015-05-21	2018-07-19	Shanghai Institutes For Biological Sciences Chinese Academy Of Sciences	Low-Oxygen-Treated Mesenchymal Stem Cell and Use Thereof
CN106589110B (zh) *	2015-10-15	2020-01-17	上海迈迹生物医药科技有限公司	包含聚合物和glp-2衍生物的缀合物
KR102502040B1 (ko)	2016-12-09	2023-02-24	질랜드 파마 에이/에스	아실화 glp-1/glp-2 이중 효능제
IL271245B2 (en)	2017-06-16	2023-10-01	Zealand Pharma As	Dosing regimen for administration of glucagon-like peptide analog (GLP-2) 2

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0607278B1 (de) *	1991-10-07	2002-04-17	The Brigham And Women's Hospital, Inc.	Verfahren zur erhöhung der darmabsorption
NZ260309A (en) *	1992-06-08	1997-07-27	Pharmacia Ab Substituted For K	Use of 1gf-2 for prevention or treatment of nutritional or gastrointestinal disorders and promoting neonatal growth
US5990077A (en) *	1995-04-14	1999-11-23	1149336 Ontario Inc.	Glucagon-like peptide-2 and its therapeutic use
EP2275438A1 (de) *	1996-04-12	2011-01-19	1149336 Ontario Inc.	Analoge des Glucagon ähnlichen Peptides-2

1996
- 1996-12-10 US US08/763,177 patent/US5952301A/en not_active Expired - Lifetime
1997
- 1997-12-10 ES ES97946986T patent/ES2193406T3/es not_active Expired - Lifetime
- 1997-12-10 AT AT97946986T patent/ATE233096T1/de active
- 1997-12-10 EP EP97946986A patent/EP0944396B1/de not_active Expired - Lifetime
- 1997-12-10 AU AU52200/98A patent/AU5220098A/en not_active Abandoned
- 1997-12-10 CA CA002274596A patent/CA2274596C/en not_active Expired - Fee Related
- 1997-12-10 WO PCT/CA1997/000945 patent/WO1998025644A1/en not_active Ceased
- 1997-12-10 PT PT97946986T patent/PT944396E/pt unknown
- 1997-12-10 DK DK97946986T patent/DK0944396T3/da active
- 1997-12-10 DE DE69719360T patent/DE69719360T2/de not_active Expired - Lifetime

Also Published As

Publication number	Publication date
CA2274596A1 (en)	1998-06-18
CA2274596C (en)	2004-11-09
DE69719360T2 (de)	2003-12-04
DE69719360D1 (de)	2003-04-03
DK0944396T3 (da)	2003-06-23
AU5220098A (en)	1998-07-03
EP0944396A1 (de)	1999-09-29
US5952301A (en)	1999-09-14
ES2193406T3 (es)	2003-11-01
WO1998025644A1 (en)	1998-06-18
EP0944396B1 (de)	2003-02-26
PT944396E (pt)	2003-07-31

Legal Events

Date

Code

Title

Description

2003-10-15

UEP

Publication of translation of european patent specification

Ref document number: 0944396

Country of ref document: EP

Publication	Publication Date	Title
DE69719360D1 (de)	2003-04-03	Zusammensetzungen und methoden zur steigerung der darmfunktion
DK0981362T3 (da)	2004-03-15	Anvendelse af GLP-2-agonister, der forbedrer funktionen af den øvre mavetarmkanal
DE69736634D1 (de)	2006-10-19	Antagonisten des intestinotrophen glp-2 peptides
EP2295453A3 (de)	2011-03-30	Appetithemmendes Peptid, Zusammensetzung und Verwendung
MXPA05002991A (es)	2005-10-05	Analogos de ghrh.
DE69731373D1 (de)	2004-12-02	Cc-chemokinzeptor c-c ckr-5, dessen derivate und verwendungen
ATE218579T1 (de)	2002-06-15	Zusammensetzungen und methoden zur behandlung von infektionen unter verwendung von indolicidin- analogen
ID26984A (id)	2001-02-22	Senyawa-senyawa sulfonamida sebagai antagonis reseptor angiotensin endotelin ganda
BR9607336A (pt)	1997-11-25	Composições de aminoácidos e utilidades das mesmas em nutrição clinica
MXPA04005053A (es)	2004-09-10	Metodos y composiciones para tratar lesiones del epitelio respiratorio.
ATE272628T1 (de)	2004-08-15	Substituierte gamma-phenyl-delta-lactone und deren analoge, und ihre verwendungen
EP0797999A3 (de)	2002-09-25	Fettleibigkeitprotein-Formulierungen
ATE232700T1 (de)	2003-03-15	Implantatkörper
TR200103339T2 (tr)	2002-04-22	Geliştirilmiş çözülürlük özelliklerine sahip yeni LHRH-antagonistleri.
DE69931482D1 (de)	2006-06-29	Isolierte peptide die aminosäuresequenzen von ny-eso-1 entsprechen und an mhc-klasse i und mhc klasse ii moleküle binden, und deren verwendungen
PE20050665A1 (es)	2005-11-02	ESTROGENOS SELECTIVOS DE 8ß-VINIL-ESTRA-1,3,5(10)-TRIEN-3,17ß-DIOL Y 17ß-FLUOR-9-VINIL-ESTRA-1,3,6(10)-TRIEN-3,16ALFA-DIOL
BR0109279A (pt)	2002-12-17	Antagonistas de lhrh, sua preparação e aplicação como medicamento
GB9711389D0 (en)	1997-07-30	Bacterial pheromones and uses therefor
RU96120655A (ru)	1998-12-10	Композиция для профилактики и лечения гриппа и орви
ATE390440T1 (de)	2008-04-15	Neuroaktive peptide
BG103905A (en)	2000-07-31	New bpc peptide salts with organoprotective activity, method for their preparation and application in medicine
BR0308978A (pt)	2006-02-21	fragmentos de peptìdeos sintéticos ativos
DE60030270D1 (de)	2006-10-05	Fettsaure analoge zur diagnose von kranzarterie erkrankungen
DE69827017D1 (de)	2004-11-18	Kombinationen von endometrium schonenden gestagenen und endometrium atrophisierenden gestagenen mit estrogenen, bei der oralen empfängnisverhütung
WO2004111086A3 (fr)	2005-09-15	ANALOGUES PEPTIDIQUES COMPRENANT AU MOINS UN RESIDU AZA-ß3 AMINOACYLE, ET LEURS UTILISATIONS, NOTAMMENT EN THERAPIE